#BEGIN_DRUGCARD DB00153

# AHFS_Codes:
Not Available

# ATC_Codes:
A11CC01

# Absorption:
Readily absorbed from small intestine (proximal or distal), requires presence of bile salts.

# Biotransformation:
Within the liver, ergocalciferol is hydroxylated to ercalcidiol (25-hydroxyergocalciferol) by the enzyme 25-hydroxylase. Within the kidney, ercalcidiol serves as a substrate for 1-alpha-hydroxylase, yielding ercalcitriol (1,25-dihydroxyergocalciferol), the biologically active form of vitamin D2.

# Brand_Mixtures:
Calcimate Plus Calcium, Potassium, Magnesium and Vitamin D (Calcium (Calcium Citrate, Calcium Malate) + Magnesium (Magnesium Oxide) + Potassium (Potassium Chloride) + Vitamin D2 (Ergocalciferol))
Calcium Magnesium 2:1 Tablets with Vitamin D (Calcium (Calcium Citrate) + Magnesium (Magnesium Oxide) + Vitamin D2 (Ergocalciferol))
Calcium and Magnesium Citrate with Vitamin D (Calcium (Calcium Citrate) + Magnesium (Magnesium Citrate) + Vitamin D (Ergocalciferol))
Centrum 8409 (Beta-Carotene + Biotin + Chromium (Chromic Chloride) + Copper (Cupric Oxide) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Iodine (Potassium Iodide) + Iron (Ferronyl) + Manganese (Manganese Sulfate) + Molybdenum (Sodium Molybdate) + Nicotinamide + Vitamin a (Vitamin a Acetate) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D2 (Ergocalciferol) + Vitamin E (Vitamin E Acetate) + Vitamin K1 (Phytonadione) + Zinc (Zinc Oxide))
Insur-All Vitamin Supplement (Biotin + Choline Bitartrate + D-Pantothenic Acid + Inositol + Nicotinamide + Vitamin a (Vitamin a Acetate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin D (Ergocalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate))
Mega Halibut Liver Oil (Vitamin a (Halibut Liver Oil) + Vitamin D (Ergocalciferol))
Msb Essentials (Beta-Carotene + Biotin + Calcium (Calcium Citrate) + Choline Dihydrogen Citrate + Chromium (Chromic Chloride) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Inositol + Iodine (Potassium Iodide) + Iron (Ferrous Fumarate) + Magnesium (Magnesium Citrate) + Manganese (Manganese Hvp Chelate) + Methionine + Molybdenum (Sodium Molybdate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate) + Selenium (Selenium Hvp Chelate) + Vitamin a (Vitamin a Acetate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 + Vitamin B2 (Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin D (Ergocalciferol) + Vitamin E (D-Alpha Tocopherol) + Zinc (Zinc Chloride))
Pre-Natal (Beta-Carotene (Provitamin a) + Biotin + Calcium (Calcium Citrate, Calcium Carbonate) + Chromium (Chromium Hvp Chelate) + Copper (Copper Hvp Chelate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Iodine (Potassium Iodide) + Iron (Iron Citrate) + Magnesium (Magnesium Hvp Chelate) + Manganese (Manganese Hvp Chelate) + Molybdenum (Molybdenum Hvp Chelate) + Nicotinamide + Potassium (Potassium Citrate) + Selenium (Selenium Hvp Chelate) + Silicon (Silicon Dioxide) + Vitamin a (Vitamin a Palmitate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 (Riboflavin Hydrochloride, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride, Pyridoxine 5' Phosphate) + Vitamin C (Calcium Ascorbate) + Vitamin D2 (Ergocalciferol) + Vitamin E (D-Alpha Tocopheryl Acid Succinate) + Zinc (Zinc Hvp Chelate))
Super Thera-M (Beta-Carotene (Provitamin a) + Biotin + Calcium (Calcium Phosphate (Dibasic)) + Chloride (Potassium Chloride) + Chromium (Chromic Chloride) + Copper (Cupric Sulfate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Iodine (Potassium Iodide, Kelp) + Iron (Ferrous Fumarate) + Magnesium (Magnesium Oxide) + Manganese (Manganese Sulfate) + Molybdenum (Sodium Molybdate) + Nicotinic Acid (Nicotinamide) + Phosphorus (Calcium Phosphate (Dibasic)) + Potassium (Potassium Chloride) + Selenium (Sodium Selenate) + Vitamin a (Vitamin a Palmitate) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D2 (Ergocalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate) + Zinc (Zinc Sulfate))
Timed Release Multi Vitamin with Chelated Minerals (Beta-Carotene (Provitamin a) + Biotin + Calcium (Calcium Hvp Chelate, Calcium Phosphate (Tribasic)) + Choline Bitartrate + Chromium (Chromium Hvp Chelate) + Copper (Copper Gluconate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Potassium Iodide, Kelp) + Iron (Iron Hvp Chelate, Ferrous Fumarate) + Magnesium (Magnesium Oxide, Magnesium Hvp Chelate) + Manganese (Manganese Hvp Chelate) + Nicotinamide + Potassium (Potassium Chloride, Potassium Citrate) + Selenium (Selenium Hvp Chelate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D (Ergocalciferol) + Vitamin E (D-Alpha Tocopheryl Acetate) + Zinc (Zinc Hvp Chelate))

# Brand_Names:
Buco-D
Calciferol
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
Daral
Davitamon D
Davitin
De-Rat Concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit Urto
Drisdol
Ercalciol
Ergorone
Ergosterol Activated
Ergosterol, Irradiated
Ertron
Fortodyl
Geltabs
Hi-Deratol
Infron
Metadee
Mulsiferol
Mykostin
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Ostelin
Radiostol
Radstein
Radsterin
Rodine C
Shock-Ferol
Shock-Ferol Sterogyl
Sterogyl
Uvesterol-D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitavel-D

# CAS_Registry_Number:
50-14-6

# ChEBI_ID:
28934

# Chemical_Formula:
C28H44O

# Chemical_IUPAC_Name:
(1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2017598

# Description:
Ergocalciferol (Vitamin D2) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from cholecalciferol in having a double bond between C22 and C23 and a methyl group at C24. [PubChem]

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Antihypocalcemic Agents
Antihypoparathyroid Agents
Bone Density Conservation Agents
Essential Vitamin
Vitamins
Vitamins (Vitamin D)

# Drug_Interactions:
Cholecalciferol	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
Colesevelam	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.

# Drug_Reference:
15585789	DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S.

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
7.3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
50 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ergocalciferol

# HET_ID:
Not Available

# Half_Life:
19 to 48 hours (however, stored in fat deposits in body for prolonged periods).

# InChI_Identifier:
InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1

# InChI_Key:
InChIKey=MECHNRXZTMCUDQ-RKHKHRCZSA-N

# Indication:
For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).

# KEGG_Compound_ID:
C05441

# KEGG_Drug_ID:
D00187

# LIMS_Drug_ID:
153

# Mechanism_Of_Action:
Activated ergocalciferol increases serum calcium and phosphate concentrations, primarily by increasing intestinal absorption of calcium and phosphate through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. 25-hydroxyergocalciferol  is the intermediary metabolite of ergocalciferol. Although this metabolite exhibits  2–5 times more activity than unactivated  ergocalciferol in curing rickets and inducing calcium absorption and mobilization (from bone) in animals, this increased activity is still insufficient to affect these functions at physiologic concentrations.  Activated ergocalciferol stimulate resorption of bone and are required for normal mineralization of bone. Physiological doses of ergocalciferol also promotes calcium reabsorption by the kidneys, but the significance of this effect is not known.

# Melting_Point:
116.5 °C

# Molecular_Weight_Avg:
396.6484

# Molecular_Weight_Mono:
396.33921603

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/vit_0265.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA449484

# Pharmacology:
Ergoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D. The principal biologic function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet. Cholecalciferol is synthesized within our bodies naturally, but if UV exposure is inadequate or the metabolism of cholecalciferol is abnormal, then an exogenous source is required. Vitamin D2 is converted to 25-hydroxyvitamin D (25OHD) in the liver, and then to the active form, 1,25-dihydroxyvitamin D (1,25(OH)2D), in the kidney. Once transformed, it binds to the vitamin D receptor, which leads to a variety of regulatory roles. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Very few foods naturally contain vitamin D. Sources that contain the vitamin include fatty fish, the liver and fat of aquatic mammals (e.g., seals, polar bears), and eggs from chickens fed vitamin D-fortified feed. As such, many countries have instituted policies to fortify certain foods with vitamin D to compensate for the potentially low exposures of skin to sunlight. Vitamin D deficiency results in inadequate mineralization of bone or compensatory skeletal demineralization and causes decreased ionized calcium concentrations in blood and a resultant increase in the production and secretion of PTH. Increase in PTH stimulates the mobilization of skeletal calcium, inhibits renal excretion of calcium, and stimulates renal excretion of phosphorus. This results in normal fasting serum calcium concentrations and low or near-normal serum phosphorus. The enhanced mobilization of skeletal calcium induced by this secondary hyperparathyroidism leads porotic bone.

# Predicted_LogP_Hydrophobicity:
7.59

# Predicted_LogS:
-6

# Predicted_Water_Solubility:
4.33e-04 g/l

# Primary_Accession_No:
DB00153

# Protein_Binding:
>99.8%

# PubChem_Compound_ID:
5280793

# PubChem_Substance_ID:
46505053

# RxList_Link:
http://www.rxlist.com/cgi/generic/ergocalciferol.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00426
NUTR00005

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Synthetic Vitamin D
Vitamin D2

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub> = 23.7 mg/kg (Orally in mice); LD<sub>50</sub> = 10 mg/kg (Orally in rats ); Nausea, vomiting and diarrhea, weight loss, irritability, weakness, fatigue, lassitude, and headache.

# Update_Date:
2013-02-08 16:19:08 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ergocalciferol

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP27B1

# Phase_1_Metabolizing_Enzyme_1_ID:
493

# Phase_1_Metabolizing_Enzyme_1_Name:
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial precursor
MTQTLKYASRVFHRVRWAPELGASLGYREYHSARRSLADIPGPSTPSFLAELFCKGGLSR
LHELQVQGAAHFGPVWLASFGTVRTVYVAAPALVEELLRQEGPRPERCSFSPWTEHRRCR
QRACGLLTAEGEEWQRLRSLLAPLLLRPQAAARYAGTLNNVVCDLVRRLRRQRGRGTGPP
ALVRDVAGEFYKFGLEGIAAVLLGSRLGCLEAQVPPDTETFIRAVGSVFVSTLLTMAMPH
WLRHLVPGPWGRLCRDWDQMFAFAQRHVERREAEAAMRNGGQPEKDLESGAHLTHFLFRE
ELPAQSILGNVTELLLAGVDTVSNTLSWALYELSRHPEVQTALHSEITAALSPGSSAYPS
ATVLSQLPLLKAVVKEVLRLYPVVPGNSRVPDKDIHVGDYIIPKNTLVTLCHYATSRDPA
QFPEPNSFRPARWLGEGPTPHPFASLPFGFGKRSCMGRRLAELELQMALAQILTHFEVQP
EPGAAPVRPKTRTVLVPERSINLQFLDR

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
O15528

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2R1

# Phase_1_Metabolizing_Enzyme_2_ID:
581

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2R1

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2R1
MWKLWRAEEGAAALGGALFLLLFALGVRQLLKQRRPMGFPPGPPGLPFIGNIYSLAASSE
LPHVYMRKQSQVYGEIFSLDLGGISTVVLNGYDVVKECLVHQSEIFADRPCLPLFMKMTK
MGGLLNSRYGRGWVDHRRLAVNSFRYFGYGQKSFESKILEETKFFNDAIETYKGRPFDFK
QLITNAVSNITNLIIFGERFTYEDTDFQHMIELFSENVELAASASVFLYNAFPWIGILPF
GKHQQLFRNAAVVYDFLSRLIEKASVNRKPQLPQHFVDAYLDEMDQGKNDPSSTFSKENL
IFSVGELIIAGTETTTNVLRWAILFMALYPNIQGQVQKEIDLIMGPNGKPSWDDKCKMPY
TEAVLHEVLRFCNIVPLGIFHATSEDAVVRGYSIPKGTTVITNLYSVHFDEKYWRDPEVF
HPERFLDSSGYFAKKEALVPFSLGRRHCLGEHLARMEMFLFFTALLQRFHLHFPHELVPD
LKPRLGMTLQPQPYLICAERR

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
Q6VVX0

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP27A1

# Phase_1_Metabolizing_Enzyme_3_ID:
606

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 27, mitochondrial

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 27, mitochondrial precursor
MAALGCARLRWALRGAGRGLCPHGARAKAAIPAALPSDKATGAPGAGPGVRRRQRSLEEI
PRLGQLRFFFQLFVQGYALQLHQLQVLYKAKYGPMWMSYLGPQMHVNLASAPLLEQVMRQ
EGKYPVRNDMELWKEHRDQHDLTYGPFTTEGHHWYQLRQALNQRLLKPAEAALYTDAFNE
VIDDFMTRLDQLRAESASGNQVSDMAQLFYYFALEAICYILFEKRIGCLQRSIPEDTVTF
VRSIGLMFQNSLYATFLPKWTRPVLPFWKRYLDGWNAIFSFGKKLIDEKLEDMEAQLQAA
GPDGIQVSGYLHFLLASGQLSPREAMGSLPELLMAGVDTTSNTLTWALYHLSKDPEIQEA
LHEEVVGVVPAGQVPQHKDFAHMPLLKAVLKETLRLYPVVPTNSRIIEKEIEVDGFLFPK
NTQFVFCHYVVSRDPTAFSEPESFQPHRWLRNSQPATPRIQHPFGSVPFGYGVRACLGRR
IAELEMQLLLARLIQKYKVVLAPETGELKSVARIVLVPNKKVGLQFLQRQC

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
Q02318

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP24A1

# Phase_1_Metabolizing_Enzyme_4_ID:
3997

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 24A1, mitochondrial

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 24A1, mitochondrial
MSSPISKSRSLAAFLQQLRSPRQPPRLVTSTAYTSPQPREVPVCPLTAGGETQNAAALPG
PTSWPLLGSLLQILWKGGLKKQHDTLVEYHKKYGKIFRMKLGSFESVHLGSPCLLEALYR
TESAYPQRLEIKPWKAYRDYRKEGYGLLILEGEDWQRVRSAFQKKLMKPGEVMKLDNKIN
EVLADFMGRIDELCDERGHVEDLYSELNKWSFESICLVLYEKRFGLLQKNAGDEAVNFIM
AIKTMMSTFGRMMVTPVELHKSLNTKVWQDHTLAWDTIFKSVKACIDNRLEKYSQQPSAD
FLCDIYHQNRLSKKELYAAVTELQLAAVETTANSLMWILYNLSRNPQVQQKLLKEIQSVL
PENQVPRAEDLRNMPYLKACLKESMRLTPSVPFTTRTLDKATVLGEYALPKGTVLMLNTQ
VLGSSEDNFEDSSQFRPERWLQEKEKINPFAHLPFGVGKRMCIGRRLAELQLHLALCWIV
RKYDIQATDNEPVEMLHSGTLVPSRELPIAFCQR

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
Q07973

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_5_ID:
4512

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
16949927	Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T: Expression of vitamin D3 receptor in kidney tumors. Hum Pathol. 2006 Oct;37(10):1268-78. Epub 2006 Jul 27.
17207992	Marks HD, Fleet JC, Peleg S: Transgenic expression of the human Vitamin D receptor (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):513-6. Epub 2007 Jan 5.
17218095	Carvallo L, Henriquez B, Olate J, van Wijnen AJ, Lian JB, Stein GS, Onate S, Stein JL, Montecino M: The 1alpha,25-dihydroxy Vitamin D3 receptor preferentially recruits the coactivator SRC-1 during up-regulation of the osteocalcin gene. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):420-4. Epub 2007 Jan 10.
17440943	Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E: Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate. 2007 Jun 15;67(9):911-23.
17519354	Ewing AK, Attner M, Chakravarti D: Novel regulatory role for human Acf1 in transcriptional repression of vitamin D3 receptor-regulated genes. Mol Endocrinol. 2007 Aug;21(8):1791-806. Epub 2007 May 22.
18290715	Jurutka PW, Bartik L, Whitfield GK, Mathern DR, Barthel TK, Gurevich M, Hsieh JC, Kaczmarska M, Haussler CA, Haussler MR: Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res. 2007 Dec;22 Suppl 2:V2-10.
20091647	Straube S, Derry S, Moore RA, McQuay HJ: Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007771.
20525913	Gallagher JC, Sai AJ: Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
VDR

# Drug_Target_1_GenBank_ID_Gene:
J03258

# Drug_Target_1_GenBank_ID_Protein:
340203

# Drug_Target_1_GeneCard_ID:
VDR

# Drug_Target_1_Gene_Name:
VDR

# Drug_Target_1_Gene_Sequence:
>1284 bp
ATGGAGGCAATGGCGGCCAGCACTTCCCTGCCTGACCCTGGAGACTTTGACCGGAACGTG
CCCCGGATCTGTGGGGTGTGTGGAGACCGAGCCACTGGCTTTCACTTCAATGCTATGACC
TGTGAAGGCTGCAAAGGCTTCTTCAGGCGAAGCATGAAGCGGAAGGCACTATTCACCTGC
CCCTTCAACGGGGACTGCCGCATCACCAAGGACAACCGACGCCACTGCCAGGCCTGCCGG
CTCAAACGCTGTGTGGACATCGGCATGATGAAGGAGTTCATTCTGACAGATGAGGAAGTG
CAGAGGAAGCGGGAGATGATCCTGAAGCGGAAGGAGGAGGAGGCCTTGAAGGACAGTCTG
CGGCCCAAGCTGTCTGAGGAGCAGCAGCGCATCATTGCCATACTGCTGGACGCCCACCAT
AAGACCTACGACCCCACCTACTCCGACTTCTGCCAGTTCCGGCCTCCAGTTCGTGTGAAT
GATGGTGGAGGGAGCCATCCTTCCAGGCCCAACTCCAGACACACTCCCAGCTTCTCTGGG
GACTCCTCCTCCTCCTGCTCAGATCACTGTATCACCTCTTCAGACATGATGGACTCGTCC
AGCTTCTCCAATCTGGATCTGAGTGAAGAAGATTCAGATGACCCTTCTGTGACCCTAGAG
CTGTCCCAGCTCTCCATGCTGCCCCACCTGGCTGACCTGGTCAGTTACAGCATCCAAAAG
GTCATTGGCTTTGCTAAGATGATACCAGGATTCAGAGACCTCACCTCTGAGGACCAGATC
GTACTGCTGAAGTCAAGTGCCATTGAGGTCATCATGTTGCGCTCCAATGAGTCCTTCACC
ATGGACGACATGTCCTGGACCTGTGGCAACCAAGACTACAAGTACCGCGTCAGTGACGTG
ACCAAAGCCGGACACAGCCTGGAGCTGATTGAGCCCCTCATCAAGTTCCAGGTGGGACTG
AAGAAGCTGAACTTGCATGAGGAGGAGCATGTCCTGCTCATGGCCATCTGCATCGTCTCC
CCAGATCGTCCTGGGGTGCAGGACGCCGCGCTGATTGAGGCCATCCAGGACCGCCTGTCC
AACACACTGCAGACGTACATCCGCTGCCGCCACCCGCCCCCGGGCAGCCACCTGCTCTAT
GCCAAGATGATCCAGAAGCTAGCCGACCTGCGCAGCCTCAATGAGGAGCACTCCAAGCAG
TACCGCTGCCTCTCCTTCCAGCCTGAGTGCAGCATGAAGCTAACGCCCCTTGTGCTCGAA
GTGTTTGGCAATGAGATCTCCTGA

# Drug_Target_1_General_Function:
Involved in transcription factor activity

# Drug_Target_1_General_References:
10678179	Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D: The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell. 2000 Jan;5(1):173-9.
10866662	Mahajan MA, Samuels HH: A new family of nuclear receptor coregulators that integrate nuclear receptor signaling through CREB-binding protein. Mol Cell Biol. 2000 Jul;20(14):5048-63.
1324736	Goto H, Chen KS, Prahl JM, DeLuca HF: A single receptor identical with that from intestine/T47D cells mediates the action of 1,25-dihydroxyvitamin D-3 in HL-60 cells. Biochim Biophys Acta. 1992 Aug 17;1132(1):103-8.
1652893	Saijo T, Ito M, Takeda E, Huq AH, Naito E, Yokota I, Sone T, Pike JW, Kuroda Y: A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single-strand conformation polymorphism analysis for heterozygous carrier detection. Am J Hum Genet. 1991 Sep;49(3):668-73.
1850412	Yu XP, Mocharla H, Hustmyer FG, Manolagas SC: Vitamin D receptor expression in human lymphocytes. Signal requirements and characterization by western blots and DNA sequencing. J Biol Chem. 1991 Apr 25;266(12):7588-95.
2177843	Sone T, Marx SJ, Liberman UA, Pike JW: A unique point mutation in the human vitamin D receptor chromosomal gene confers hereditary resistance to 1,25-dihydroxyvitamin D3. Mol Endocrinol. 1990 Apr;4(4):623-31.
2835767	Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O'Malley BW: Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A. 1988 May;85(10):3294-8.
2849209	Hughes MR, Malloy PJ, Kieback DG, Kesterson RA, Pike JW, Feldman D, O'Malley BW: Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science. 1988 Dec 23;242(4886):1702-5.
7828346	Rut AR, Hewison M, Kristjansson K, Luisi B, Hughes MR, O'Riordan JL: Two mutations causing vitamin D resistant rickets: modelling on the basis of steroid hormone receptor DNA-binding domain crystal structures. Clin Endocrinol (Oxf). 1994 Nov;41(5):581-90.
8106618	Malloy PJ, Weisman Y, Feldman D: Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. J Clin Endocrinol Metab. 1994 Feb;78(2):313-6.
8381803	Yagi H, Ozono K, Miyake H, Nagashima K, Kuroume T, Pike JW: A new point mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor in a kindred with hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Clin Endocrinol Metab. 1993 Feb;76(2):509-12.
8392085	Kristjansson K, Rut AR, Hewison M, O'Riordan JL, Hughes MR: Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. J Clin Invest. 1993 Jul;92(1):12-6.
8675579	Lin NU, Malloy PJ, Sakati N, al-Ashwal A, Feldman D: A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Clin Endocrinol Metab. 1996 Jul;81(7):2564-9.
8961271	Whitfield GK, Selznick SH, Haussler CA, Hsieh JC, Galligan MA, Jurutka PW, Thompson PD, Lee SM, Zerwekh JE, Haussler MR: Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. Mol Endocrinol. 1996 Dec;10(12):1617-31.
9005998	Malloy PJ, Eccleshall TR, Gross C, Van Maldergem L, Bouillon R, Feldman D: Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. J Clin Invest. 1997 Jan 15;99(2):297-304.
9212063	Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, Inoue Y, Morita K, Takeda E, Pike JW: Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol. 1997 Jul;11(8):1165-79.
9267036	Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997 Aug 8;90(3):569-80.

# Drug_Target_1_HGNC_ID:
HGNC:12679

# Drug_Target_1_HPRD_ID:
03463

# Drug_Target_1_ID:
856

# Drug_Target_1_Locus:
12q13.11

# Drug_Target_1_Molecular_Weight:
48290

# Drug_Target_1_Name:
Vitamin D3 receptor

# Drug_Target_1_Number_of_Residues:
427

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00104	Hormone_recep
PF00105	zf-C4

# Drug_Target_1_Protein_Sequence:
>Vitamin D3 receptor
MEAMAASTSLPDPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRRSMKRKALFTC
PFNGDCRITKDNRRHCQACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEALKDSL
RPKLSEEQQRIIAILLDAHHKTYDPTYSDFCQFRPPVRVNDGGGSHPSRPNSRHTPSFSG
DSSSSCSDHCITSSDMMDSSSFSNLDLSEEDSDDPSVTLELSQLSMLPHLADLVSYSIQK
VIGFAKMIPGFRDLTSEDQIVLLKSSAIEVIMLRSNESFTMDDMSWTCGNQDYKYRVSDV
TKAGHSLELIEPLIKFQVGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLS
NTLQTYIRCRHPPPGSHLLYAKMIQKLADLRSLNEEHSKQYRCLSFQPECSMKLTPLVLE
VFGNEIS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Nuclear hormone receptor. VDR mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes

# Drug_Target_1_SwissProt_ID:
P11473

# Drug_Target_1_SwissProt_Name:
VDR_HUMAN

# Drug_Target_1_Synonyms:
1,25-dihydroxyvitamin D3 receptor
VDR

# Drug_Target_1_Theoretical_pI:
6.50

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00153
